Medicinal mushroom supplement
Lion's Mane
Lion's Mane has no human half-life figure in the sources used here; the app lists 8 hours, and a rat study of erinacine A reports 491 minutes (about 8.2 hours) after oral dosing.1
- Compound
- Lion's Mane
- Symbol
- LM
- Family
- Supplements
- Parts
- 13
- References
- 16
- Checked
- Last reviewed . Sources are listed below.
Overview
Lion's Mane is the common name of Hericium erinaceus, which one trial group describes as "an edible mushroom".2 The app files it as a medicinal mushroom supplement taken by mouth and grades its evidence as emerging. Li and colleagues describe hericenones and erinacines as "the two important classes of constitutes isolated from the fruiting body and mycelium of H. erinaceus, respectively".3 The app's note makes the same split, with hericenones in the fruiting body and erinacines in the mycelium.
Surendran and colleagues write that "Not all LMM extracts contain equal proportions of purported bioactives".4 Saitsu and colleagues tested supplements "containing fruiting body of H. erinaceus".5 Li and colleagues used mycelia "enriched with 5 mg/g erinacine A".3 Vigna and colleagues used a supplement whose "composition was 80% bulk mycelia and 20% fruiting body extract".6
No DailyMed label for a Lion's Mane product was identified, so no labelled strength, indication or storage statement is given here.
How it works
Sources in this part
The mechanism evidence below comes from cells and animals. Mori and colleagues (Tohoku University, Biological and Pharmaceutical Bulletin, 2008) tested ethanol extracts of four edible mushrooms in 1321N1 human astrocytoma cells and report that "only H. erinaceus extract promoted NGF mRNA expression in a concentration-dependent manner".7 The same paper reports that hericenones C, D and E "failed to promote NGF gene expression in 1321N1 cells" and concludes that the active compounds "are not hericenones".7 In mice, feed containing 5% H. erinaceus dry powder for 7 days raised NGF mRNA expression in the hippocampus.7 The app's note says hericenones and erinacines upregulate nerve growth factor; the hericenone result in these cells points the other way, and none of this was measured in people.
Tsai and colleagues (Molecules, 2021) gave rats an erinacine A-enriched mycelia extract by mouth and report that erinacine A "was detected in brain at 1 h after oral dosing and reached the peak at 8 h".1 They conclude that erinacine A "can penetrate the blood-brain barrier of rats by the means of passive diffusion".1 In a single landrace pig given erinacine A intravenously, Chen and colleagues (Heliyon, 2024) report that in cerebrospinal fluid "erinacine A was detected after 15 min".8 These are animal results for one component, erinacine A, not for the whole mushroom or for people. The Chen pig study describes itself as a pilot in a single pig, and its declaration of competing interests lists employment at Grape King Bio Ltd for five authors and at the Agricultural Technology Research Institute for three.8 Docherty and colleagues, discussing the timing of their post-dose tests, write that "without human bioavailability data it is difficult to make this decision".2
Half-life and pharmacokinetics
- Half-life (app's figure, not measured in people)
- ~8 h
- Bioavailability (app's figure, not measured in people)
- 50%
- Typical dose (app's figure, no label dose identified)
- 500–1000 mg/day
- Route
- Oral
- Time to peak (app's figure, not measured in people)
- ~3 h
Sources in this part
The second column of the table holds the app's own figures, shown beside what the sources report.
| Parameter | App's figure | Reported in the sources |
|---|---|---|
| Half-life | ~8 h | Rats, oral erinacine A-enriched mycelia extract 2.381 g/kg (equivalent to 50 mg/kg erinacine A): T1/2 491.22 ± 111.70 min (about 8.2 h), n = 6; rats, intravenous erinacine A 5 mg/kg: T1/2 4.37 ± 4.55 min, n = 6; one pig, intravenous erinacine A 5 mg/kg: terminal half-life 20.85 ± 0.03 min; no human figure identified1,8 |
| Bioavailability | 50% | Rats: absolute oral bioavailability of erinacine A estimated as 24.39% (oral mycelia extract 2.381 g/kg, equivalent to 50 mg/kg erinacine A, against intravenous erinacine A 5 mg/kg), n = 6; no human figure identified1 |
| Time to peak | ~3 h | Rats: plasma Tmax 360.00 ± 131.45 min (6 h); brain erinacine A reached its peak at 8 h; no human figure identified1 |
| Volume of distribution | Not listed | Pig, intravenous erinacine A: 4.24 ± 0.00 L/kg8 |
The app's 8-hour half-life is close to the rat figure for erinacine A, but the app's 50% bioavailability is about twice the rat figure and its 3-hour peak is half the rat plasma Tmax. The rat data are for one component after dosing with a mycelia extract, so they are not a measurement of the whole mushroom or of people. Tsai and colleagues report no external funding and no conflict of interest, and list Grape King Bio Ltd. in the affiliations of three authors.1
Human studies
The seven trials in the table differ in product, dose, length and population, so their results are not pooled here.
| Study and year | Design | People | Dose and length | Main result |
|---|---|---|---|---|
| Mori and colleagues (Hokuto Corporation, Japan), Phytotherapy Research 20099 | Double-blind, parallel-group, placebo-controlled; 16 weeks of intake and 4 weeks of observation after9 | 30 Japanese men and women aged 50 to 80 with mild cognitive impairment, randomised to two groups of 159 | Four 250 mg tablets of 96% dry powder, three times a day, for 16 weeks9 | Scores on a scale based on the Revised Hasegawa Dementia Scale were significantly higher than placebo at weeks 8, 12 and 16 and fell significantly 4 weeks after intake ended; "Laboratory tests showed no adverse effect"9 |
| Nagano and colleagues (Kyoto Bunkyo University, Japan), Biomedical Research 201010 | Randomised, placebo-controlled; cookies for 4 weeks10 | 30 females, described by a later paper as menopausal women10,3 | Cookies for 4 weeks; a later paper gives four cookies a day, each with 0.5 g of powdered fruiting body10,2 | Depression (CES-D) and indefinite-complaints (ICI) scores were significantly lower after intake than before; against placebo, two ICI items were significantly lower and three others "tended to be lower"; the authors write that intake "has the possibility to reduce depression and anxiety"10 |
| Vigna and colleagues (IRCCS Policlinico, Milan), Evidence-Based Complementary and Alternative Medicine 20196 | Randomised to a control group or a Hericium group, no placebo; both groups on a low-calorie diet6 | 77 volunteers with overweight or obesity and a mood and/or sleep disorder or binge eating (control n = 37, Hericium n = 40)6 | Three capsules a day of a supplement (80% mycelia, 20% fruiting body extract) for 8 weeks6 | Depression, anxiety and sleep disorder scores decreased; circulating pro-BDNF rose with no significant change in BDNF; three drop-outs at T1 and five at T2 in the Hericium group, none in the control group; the authors list "the limited number of patients and the lack of a placebo group" as limitations; the supplement was provided by A.V.D. Reform s.r.l.6 |
| Saitsu and colleagues (Kindai University and others, Japan), Biomedical Research 20195 | Randomised, double-blind, placebo-controlled, parallel-group, multicentre5 | 31 participants with an average age of 61.3 years, as reported by a later paper3 | Fruiting body supplement for 12 weeks; a later paper gives 3.2 g of powdered fruiting body daily5,2 | Of three tests, "MMSE alone showed that oral intake of H. erinaceus significantly improved cognitive functions"; a later paper notes "no additional effects were observed on other measures"5,2 |
| Li and colleagues (Grape King Bio and Chung Shan Medical University, Taiwan), Frontiers in Aging Neuroscience 20203 | Pilot, double-blind, randomised, placebo-controlled, fixed-dose; 49-week treatment period3 | Patients with mild Alzheimer's disease; 49 randomised, 41 analysed (20 erinacine A mycelia, 21 placebo)3 | Three 350 mg capsules a day, each with 5 mg/g erinacine A, for 49 weeks3 | MMSE rose from 21.75 ± 6.1 to 23.2 ± 5.92 (p = 0.035) in the treated group, but "all the pairwise comparisons of the MMSE test were not statistically significant"; IADL differed at week 49 (6.7 ± 2.47 vs 5 ± 2.7; p = 0.012); no significant intra-group or inter-group CASI difference; NPI comparison to baseline not significant in either group (p = 0.077 and 0.163); 7 of 49 left the study (side effects in 3 treated and 1 placebo, unsatisfactory efficacy in 2 treated and 1 placebo) and 1 was lost to follow-up3 |
| Docherty and colleagues (Northumbria University, UK), Nutrients 20232 | Pilot, randomised, double-blind, placebo-controlled, parallel groups; tests 60 min after a first dose and after 28 days2 | 43 healthy adults aged 18 to 45 in the acute analysis, 41 in the 28-day analysis2 | 1.8 g a day (three capsules); a single dose, then 28 days2 | Stroop task faster at 60 min (p = 0.005); immediate word recall less accurate after the dose; placebo group recalled more delayed words at day 29; stress scale trend (p = 0.051), no difference on the Perceived Stress Scale; "null and limited negative findings were also observed"2 |
| Surendran and colleagues (University of Surrey, UK), Frontiers in Nutrition 20254 | Acute, randomised, placebo-controlled, double-blind, cross-over4 | 18 healthy participants aged 18 to 354 | A single dose of 3 g of a 10:1 fruiting body extract; tests at baseline and 90 minutes after4 | No significant effect on composite measures of global cognitive function and mood; better pegboard performance at 90 minutes, while acute consumption "appeared to impair performance on the Flanker and Trail making B tests"; the authors call the study "inconclusive"4 |
Deeper analysis: Li and colleagues, erinacine A-enriched mycelia in mild Alzheimer's disease (2020)
Li and colleagues (Frontiers in Aging Neuroscience, 2020) ran a "1-year, double-blind, randomized, placebo-controlled, fixed-dose intervention pilot trial" at Chung Shan Medical University in patients with mild Alzheimer's disease.3 Of 68 patients recruited, 19 declined to take part, 49 were randomised, seven withdrew consent, one was lost to follow-up and 41 completed (EAHE group n = 20, placebo group n = 21).3 The treated group took three 350 mg capsules a day, each containing 5 mg/g erinacine A, with meals for 49 weeks, after a 3-week no-drug screening period.3 Within the treated group MMSE rose from 21.75 ± 6.1 to 23.2 ± 5.92 (p = 0.035) while the placebo group showed no significant change, yet "all the pairwise comparisons of the MMSE test were not statistically significant".3 The IADL difference at week 49 was 6.7 ± 2.47 against 5 ± 2.7 (p = 0.012), while CASI showed a within-group trend in each arm (treated 71.75 to 75.35, p = 0.058; placebo 73.52 to 69.67, p = 0.064) and no significant between-group difference.3 The NPI comparison to baseline "showed no significant difference in both groups".3 In the eye tests, the authors write that "No significant differences were observed in the ophthalmologic examination in this study except for a higher CS OS at week 49 after EAHE treatment", and that best-corrected visual acuity differed between the groups at baseline.3 On adverse events, 1 participant was lost to follow-up and 7 (14.3%) left the study; the reasons included side effects in 3 treated and 1 placebo participants, and the authors report possible or probable side effects of "abdominal discomfort, nausea, and skin rash" in the treated group and nausea in the placebo group.3 The same paper gives unsatisfactory efficacy as a further reason for leaving, in 2 participants from the treated group and 1 from the placebo group.3 The authors add that "it remains a challenge to identify if these adverse events were caused by EAHE consumption" and that "a larger study is required to determine the benefits of EAHE consumption for patients with MCI or mild AD".3 They describe the trial as a pilot to assess efficacy and the feasibility of a larger trial, and the paper's own conclusion calls the product "safe, well-tolerated".3 On funding, the paper states that "Grape King Bio Inc., provided support in the form of salaries for the authors I-CL, W-PC, L-YL, Y-WC, Y-PC, and research materials", while having no additional role in design, data analysis, the decision to publish or the manuscript.3 The registry entry names Chung Shan Medical University as lead sponsor with Grape King Bio Ltd. as an industry collaborator, lists enrolment as 68 (actual), and shows a start date of 22 May 2015, a completion date of 10 May 2017 and a first submission on 15 August 2019.11
Deeper analysis: Mori and colleagues, mild cognitive impairment (2009)
Mori and colleagues (Phytotherapy Research, 2009) report a double-blind, parallel-group, placebo-controlled trial in Japanese men and women aged 50 to 80 with mild cognitive impairment, where 30 people were randomised into two groups of 15.9 The author affiliation is the Mushroom Laboratory of Hokuto Corporation; the PubMed record that was read lists no funding statement, and the authors' own limitations are not in that record.9 Li and colleagues later wrote that in this trial "the active constituents, representative markers, and major chemical constituents of H. erinaceus tablets have not been extensively addressed".3
Deeper analysis: Docherty and colleagues, healthy young adults (2023)
Docherty and colleagues (Northumbria University, Nutrients, 2023) randomised 43 healthy adults aged 18 to 45 to 1.8 g a day of a Lion's Mane product or placebo capsules, with 41 in the 28-day analysis.2 After one dose, participants performed significantly quicker on the Stroop task at the 1 h post-dose assessment (p = 0.005); in the planned comparisons the Lion's Mane group's mean was 688.05 msecs after the dose against 737.70 msecs at baseline.2 The authors note that this speed result "was only observed on a singular task (Stroop) and was not seen for any other task nor the global speed of performance domain".2 They also report that after the dose "the participants performed less accurately on the immediate word recall", and that after 28 days the placebo group did better on delayed word recall.2 Subjective stress showed "a trend" (p = 0.051) on the Stress Visual Analogue Scales after 28 days, with no difference on the Perceived Stress Scale.2 The authors state that "an inherent limitation of this trial is the small sample size utilized" and that it "was likely underpowered to detect the probable, modest cognition-enhancing effects in a healthy sample".2 The methods state that participants "reported any adverse health outcomes", and the results text read does not give adverse event counts.2 The product was provided by Sempera Organics, which "had no role in the design of the study", and the paper states "This research received no additional external funding" and no conflict of interest.2
Deeper analysis: Surendran and colleagues, single dose in healthy young adults (2025)
Surendran and colleagues (University of Surrey, Frontiers in Nutrition, 2025) report no significant effect on composite measures of global cognitive function and mood, an improvement on the pegboard test, and that this "finding was contradicted by negative results in other tests".4 The authors name the negative tests as the Flanker and Trail making B, and write that, with a relatively small sample size, all cognitive results call for caution and for replication in future studies to validate the findings.4 The authors attribute the absence of a mood effect to "the research being conducted on healthy participants, the dosage of H. erinaceus administered and the acute design of the study with only a single dose consumed".4 Two authors are employed by Beyond Alcohol Ltd., which the paper says uses plants containing Hericium erinaceus in its products, and the company contributed towards the publication fee.4
Doses reported in studies and on labels
No label dose was identified. The app lists a typical dose of 500 to 1000 mg/day. The table lists what each study gave; every daily amount stated as a total in the table is above the top of the app's range.
| Source | Material | Amount and length | People |
|---|---|---|---|
| Mori 20099 | Tablets of 96% Yamabushitake dry powder | Four 250 mg tablets three times a day (3 g a day) for 16 weeks | Adults aged 50 to 80 with mild cognitive impairment |
| Nagano 201010,2 | Cookies with powdered fruiting body | Four cookies a day, each with 0.5 g, for 4 weeks (2 g a day) | 30 females |
| Saitsu 20195,2 | Supplement containing fruiting body | 3.2 g a day of powdered fruiting body for 12 weeks, as reported by a later paper | Adults aged 50 or older |
| Vigna 20196 | Supplement of 80% bulk mycelia and 20% fruiting body extract | Three capsules a day for 8 weeks; the paper's composition table lists 400 mg mycelium and 100 mg fruiting body extract per capsule, 1200 mg and 300 mg a day (1,500 mg a day by that arithmetic) | Adults with overweight or obesity on a low-calorie diet |
| Li 20203 | Mycelia with 5 mg/g erinacine A | Three 350 mg capsules a day (1,050 mg by that arithmetic) for 49 weeks | Mild Alzheimer's disease |
| Docherty 20232 | Capsules of a proprietary Hericium erinaceus blend | Three capsules a day, 1.8 g a day; a single dose and 28 days | Healthy adults aged 18 to 45 |
| Surendran 20254 | Fruiting body extract, 10:1 | 3 g as a single dose | Healthy adults aged 18 to 35 |
| Registry NCT0493996112 | Hericium erinaceus capsules, "containing 5 milligram of erinacines", prepared by collaborator-investigator MycoMedica; randomised, placebo-controlled | Registry arm description: 8 gram a day (6 capsules); measurements at baseline and ten weeks | Older adults aged 55 to 75; 40 enrolled; status COMPLETED |
Side effects reported
Mori and colleagues report that "Laboratory tests showed no adverse effect of Yamabushitake" in their 16-week trial.9 The 2025 systematic review's table of adverse events lists, for the Mori trial, "Mild stomach discomfort & diarrhea in 7 Yamabushitake vs. 6 placebo; no treatment needed", and, for the Nagano cookie trial, "One participant reported epimenorrhea but was excluded from the sample, not attributed to HE".14 In the Li trial, four participants dropped out because of side effects (3 treated, 1 placebo), and the listed possible or probable side effects were abdominal discomfort, nausea and skin rash in the treated group and nausea in the placebo group.3 In the Vigna trial the Hericium group had three drop-outs at T1 and five at T2 against none in the control group; the reasons are not part of the text quoted here.6 A 2025 systematic review (Menon and colleagues, Frontiers in Nutrition) states: "Although commonly unreported, potential side effects of HE include stomach discomfort, headache, and allergic reactions".14 The same review describes "One case report from Japan documented acute respiratory distress syndrome in a 63-year-old male following prolonged use of HE", and says the cause "cannot be entirely attributed to HE without further investigation".14 That account comes from the review, not from the original case report, which was not read. In describing that case report, the review states that "A lymphocyte reaction test with the extract yielded significantly positive results" and that "The report concluded that HE contains a compound capable of triggering an allergic reaction".14 In rats, Lee and colleagues (a Grape King Bio-affiliated group) fed erinacine A-enriched mycelia at 0, 875, 1750 and 2625 mg/kg body weight for 13 weeks and report "neither any mortalities nor noticeable toxicological effects".13 Docherty and colleagues did not report adverse event counts in the text read, and Surendran and colleagues' text read does not report them either.2,4
Bloodwork and markers
Sources in this part
The app lists no health markers to monitor. Li and colleagues measured blood markers at baseline, week 25 and week 49, and report that "only the placebo group observed significantly lowered biomarkers such as calcium, albumin, apolipoprotein E4, hemoglobin, and brain-derived neurotrophic factor".3 The same paper cautions that "an altered diet or a multiplicity of environmental changes could change the blood proteome as well as ions", and that serum biochemical and hematological data after long-term consumption in humans are "important to consider".3 Vigna and colleagues report that H. erinaceus "increased circulating pro-BDNF levels without any significant change in BDNF circulating levels".6
Regulatory and anti-doping status
The 2026 WADA Prohibited List came into effect on 1 January 2026, and no entry naming Hericium, lion's mane or mushrooms appears in the text of it that was read.15 That check covers named entries in the text read, not every compound a product might contain. No DailyMed label for a Lion's Mane product was identified in the search run. The one FDA document located that concerns H. erinaceus is a letter of 27 September 2023 about GRAS Notice GRN 001124, whose subject is "β-glucans from Hericium erinaceus strain BCRC 35669".16 The letter says the FDA granted a request to cease its evaluation of GRN 001124, so it is neither an approval nor a rejection of Lion's Mane products.16 Surendran and colleagues state that extracts derived from the fruiting body of Hericium erinaceus are regulated under an EU novel foods listing.4
What is not known
Sources in this part
On 16 November 2026 the query "erinacine A pharmacokinetics" in PubMed returned 3 records, none in people, so the app's half-life, bioavailability and time to peak have no human measurement beside them in the sources used here. Surendran and colleagues call for work to "establish optimal dosage and the time to peak concentration of H. erinaceus bioactives in the human brain".4 The trials above used different products, from fruiting body powder to erinacine A-enriched mycelia, so a result in one is not a result for the others. No controlled trial in people of Lion's Mane combined with BPC-157 was identified in PubMed or ClinicalTrials.gov, where searches for "Hericium BPC-157" and "lion's mane BPC-157" returned no records. The app's note describes the BPC-157 pairing as a "nerve repair narrative"; none of the studies described tested nerve repair in people.
Frequently asked questions
What is the half-life of Lion's Mane?
No human half-life for Lion's Mane was identified, and the app lists 8 hours. A rat study of oral erinacine A-enriched mycelia extract reports a half-life of 491.22 ± 111.70 minutes (about 8.2 hours), n = 6.1
What is the bioavailability of Lion's Mane?
The app lists 50%, and the only measurement identified in the searches is 24.39% absolute oral bioavailability of erinacine A in rats.1
How long does Lion's Mane take to reach its peak?
The app lists about 3 hours, and no human time to peak was identified. In rats, plasma erinacine A peaked at a mean of 360.00 ± 131.45 minutes after the oral extract and brain erinacine A reached its peak at 8 hours.1
Is Lion's Mane banned by WADA?
No entry naming Hericium, lion's mane or mushrooms appears in the text of the 2026 WADA Prohibited List that was read.15
Does Lion's Mane raise nerve growth factor in people?
Has Lion's Mane been tested in people with Alzheimer's disease?
What side effects have been reported for Lion's Mane?
In the Li trial, 4 participants (3 treated, 1 placebo) dropped out because of side effects, and abdominal discomfort, nausea and skin rash were listed in the treated group.3 A systematic review lists "stomach discomfort, headache, and allergic reactions" as potential side effects and describes one case report of acute respiratory distress syndrome in a 63-year-old man.14
What is the difference between hericenones and erinacines?
Hericenones are isolated from the fruiting body and erinacines from the mycelium of H. erinaceus, as Li and colleagues describe.3
Guides, tools and comparisons
References
- Tsai PC, et al. Preclinical Bioavailability, Tissue Distribution, and Protein Binding Studies of Erinacine A, a Bioactive Compound from Hericium erinaceus Mycelia Using Validated LC-MS/MS Method. Molecules 2021. PMID 34361662
- Docherty S, et al. The Acute and Chronic Effects of Lion's Mane Mushroom Supplementation on Cognitive Function, Stress and Mood in Young Adults: A Double-Blind, Parallel Groups, Pilot Study. Nutrients 2023. PMID 38004235
- Li IC, et al. Prevention of Early Alzheimer's Disease by Erinacine A-Enriched Hericium erinaceus Mycelia Pilot Double-Blind Placebo-Controlled Study. Front Aging Neurosci 2020. PMID 32581767
- Surendran G, et al. Acute effects of a standardised extract of Hericium erinaceus (Lion's Mane mushroom) on cognition and mood in healthy younger adults: a double-blind randomised placebo-controlled study. Front Nutr 2025. PMID 40276537
- Saitsu Y, et al. Improvement of cognitive functions by oral intake of Hericium erinaceus. Biomed Res 2019. PMID 31413233
- Vigna L, et al. Hericium erinaceus Improves Mood and Sleep Disorders in Patients Affected by Overweight or Obesity: Could Circulating Pro-BDNF and BDNF Be Potential Biomarkers? Evid Based Complement Alternat Med 2019. PMID 31118969
- Mori K, et al. Nerve growth factor-inducing activity of Hericium erinaceus in 1321N1 human astrocytoma cells. Biol Pharm Bull 2008. PMID 18758067
- Chen YY, et al. A pilot pharmacokinetic and Metabolite identification study of Erinacine A in a Single landrace pig model. Heliyon 2024. PMID 39315194
- Mori K, et al. Improving effects of the mushroom Yamabushitake (Hericium erinaceus) on mild cognitive impairment: a double-blind placebo-controlled clinical trial. Phytother Res 2009. PMID 18844328
- Nagano M, et al. Reduction of depression and anxiety by 4 weeks Hericium erinaceus intake. Biomed Res 2010. PMID 20834180
- Chung Shan Medical University. Erinacine A-enriched Hericium Erinaceus Mycelia for Improvement of Recognition, Vision, and Functional MRI Alterations. ClinicalTrials.gov NCT04065061. NCT04065061
- University of Primorska. Effects of Hericium Erinaceus on Microbiota and Cognition. ClinicalTrials.gov NCT04939961. NCT04939961
- Lee LY, et al. Thirteen-Week Oral Toxicity Evaluation of Erinacine A-Enriched Lion's Mane Medicinal Mushroom, Hericium erinaceus (Agaricomycetes), Mycelia in Sprague-Dawley Rats. Int J Med Mushrooms 2019. PMID 31002635
- Menon A, et al. Benefits, side effects, and uses of Hericium erinaceus as a supplement: a systematic review. Front Nutr 2025. PMID 40959699
- World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. WADA list
- US Food and Drug Administration. Letter to Super Beta Glucan, Inc. regarding GRAS Notice No. GRN 001124, 27 September 2023. FDA letter